Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Trump Media and Technology Group Corp (DJT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Trump Media and Technology Group Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Trump Media and Technology Group Corp trades at $8.45 (market cap $2.25B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals.
| ACAD | DJT | |
|---|---|---|
Market Cap | $4.49B | $2.25B |
Sector | Health | Media |
52-Week High | $28.06 | $19.86 |
52-Week Low | $20.06 | $7.06 |
Enterprise Value | $3.69B | $2.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DJT trades at $8.66, up 1.41% today, with a bullish technical signal from moving averages despite neutral oscillators. Fundamentally, the company reported minimal revenue of $3.68M in 2025 with a massive net loss of -$712M, resulting in negative profit margins and ROE. Recent news highlights significant stock declines, with the company's market value dropping nearly 75% from its peak amid strategic shifts including a planned merger with TAE Technologies.
The outlook remains highly speculative with severe profitability challenges offset by potential catalysts from the TAE merger. Key risks include persistent losses, minimal revenue growth, and high volatility. Institutional sentiment is cautious given the extreme valuation metrics and operational uncertainties facing the social media platform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →
